A detailed history of Crewe Advisors LLC transactions in Geron Corp stock. As of the latest transaction made, Crewe Advisors LLC holds 8,300 shares of GERN stock, worth $30,378. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,300
Previous 9,700 14.43%
Holding current value
$30,378
Previous $41,000 9.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.17 - $4.99 $5,838 - $6,986
-1,400 Reduced 14.43%
8,300 $37,000
Q1 2024

May 13, 2024

BUY
$1.75 - $3.44 $15,225 - $29,928
8,700 Added 870.0%
9,700 $32,000
Q4 2023

Feb 09, 2024

SELL
$1.74 - $2.31 $1,740 - $2,310
-1,000 Reduced 50.0%
1,000 $2,000
Q1 2021

Apr 21, 2021

BUY
$1.52 - $2.1 $1,520 - $2,100
1,000 Added 100.0%
2,000 $3,000
Q3 2019

Nov 06, 2019

BUY
$1.15 - $1.59 $1,150 - $1,590
1,000 New
1,000 $1,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.38B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.